In February 2010, aztreonam for inhalation solution (Cayston ... symptoms in patients with cystic fibrosis infected with Pseudomonas aeruginosa. At present, treatment with tobramycin involves ...

aeruginosa infection can often receive adequate MSSA coverage with antipseudomonal agents (with the exception of ceftazidime and aztreonam). The intravenous options for MRSA are generally limited ...

Purpose The pharmacology, safety, efficacy, pharmacokinetics, pharmacodynamics, current place in therapy, and potential future therapeutic uses of inhaled aztreonam are reviewed. Conclusion ...